Tel.: +49 89 315 700-0

COVID 19

With “Duovid-19” BIOMED-Labordiagnostik GmbH establishes its first RNA control for monitoring and validation of common molecular diagnostic SARS-CoV-2 PCR tests on the market. The control is “for research use only”.

The highly infectious coronavirus SARS-CoV-2, which causes the novel disease COVID-19, can cause severe damage to various organs and even death in patients. Therefore, the detection of diseased persons is a crucial factor in limiting the spread and containing the pandemic.

The Positive Control Duovid-19 from BIOMED is a lyophilized RNA control. It is used as in vitro control material for the diagnosis of an infection with the human pathogen SARS-CoV-2 (COVID-19) using molecular diagnostic tests. An important factor of the COVID-19 control is that it is a control with standardised positive material of defined concentration. Duovid-19 contains synthetic RNA transcripts corresponding to the N, S, E and Orf1ab regions of the genome of the human pathogenic virus SARS-CoV-2. Duovid-19 is used as a positive control for reverse transcription, PCR amplification and detection, analogous to a patient sample.

The control kit contains solutions with SARS-CoV-2 specific RNA in two different concentration ranges with defined copy number/µL, which can be used as controls for weak positive and extremely weak positive samples in the most commonly used COVID-19 PCR nucleic acid test methods.

According to the guidelines of the German Medical Association (RiLiBÄK), a PCR must be checked at each run with an external quality control such as the Duovid-19 control.

With the introduction of the PCR quality control Duovid-19, BIOMED-Labordiagnostik GmbH now supports medical laboratories in their daily fight against the corona virus. For a detailed product consultation the team of BIOMED-Labordiagnostik GmbH is available by phone or email.

Back to news overview
2020-07-28T08:44:31+02:00